Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 153 clinical trials
Carfilzomib Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

This phase I/II trial studies the side effects and best dose of carfilzomib when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with diffuse large B-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes …

ejection fraction
cyclophosphamide
combination chemotherapy
b-cell lymphoma
antineoplastic
  • 8 views
  • 29 Mar, 2021
  • 5 locations
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

After consolidation therapy adult patients (18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

cell transplantation
residual tumor
consolidation therapy
  • 1 views
  • 22 Feb, 2021
  • 90 locations
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma

A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.

  • 0 views
  • 27 Jan, 2021
  • 5 locations
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)

The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL). Apply uniform treatment that enables a joint analysis of results strong enough to make conclusions on specific subgroups of patients (genotypic subtypes, particularly LAL Bcr/abl positive, phenotype, or strata of …

idarubicin
ara-c
lymphoid leukemia
bcr-abl protein
methotrexate
  • 28 views
  • 02 Feb, 2021
  • 1 location
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

The incidence of Hodgkin's lymphoma (HL) in Chinese children and adolescents is only 1 / 10 of that in Europe and the United States, which is a "rare" childhood tumor. Due to the "drug shortage" and extremely low incidence, it has brought great difficulties to the domestic clinical research and …

  • 0 views
  • 05 Feb, 2021
  • 3 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. …

cyclophosphamide
remission
direct bilirubin
cytarabine
corticosteroids
  • 45 views
  • 30 Apr, 2021
  • 455 locations
Efficacy and Safety of Sirolimus to Vascular Anomalies

To evaluate the safety and efficacy of Sirolimus in complicated vascular anomalies in Chinese children

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: Determine the progression-free survival. In an exploratory manner examine the extent of activation of the VEGFR pathway in pheochromocytoma/paraganglioma using a semi-quantitative immunohistochemistry assay and examine the relationship with response …

iobenguane
ag-013736
immunohistochemistry
pheochromocytoma
neutrophil count
  • 1 views
  • 22 Jan, 2021
  • 1 location
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a …

  • 0 views
  • 23 Jan, 2021
  • 1 location
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide for adult T-ALL/LBL. Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated from induction therapy to maintenance therapy, along with …

cyclophosphamide
cell transplantation
idarubicin
cytarabine
adult t-cell leukemia/lymphoma
  • 13 views
  • 22 Jan, 2021